YIH
EIGR

Y-Intercept (HK)’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Y-Intercept (HK)’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,374
Closed -$114K – 1751
2023
Q2 		$114K Buy
+5,374
New +$166K 0.01% 1058

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Y-Intercept (HK)'s EIGR Position: Q3 2023 in Review

Y-Intercept (HK) sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q3 2023, closing a stake of 5,374 shares — an estimated $114K sold.

Y-Intercept (HK) first reported a position in EIGR in Q2 2023 and held it in 1 quarter. The position peaked at $114K in Q2 2023. 51 funds tracked by Wall St. Rank hold EIGR as of Q3 2023.

  • Y-Intercept (HK) reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 5,374 Eiger BioPharmaceuticals, Inc. shares in Q3 2023, an estimated $114K.
  • Y-Intercept (HK) first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2023 and held it in 1 quarter.
  • Y-Intercept (HK)'s Eiger BioPharmaceuticals, Inc. position peaked at $114K in Q2 2023.
  • 51 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.